Table 1 A/H1N1 HA antibody levels in relation to age.

From: A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis

Assay

Age

NT1 patients AU or U/ml median (range)

Healthy controls AU or U/ml median (range)

p1

p2

p3

Exploratory study

LIPS

0–13

119,108 (21,108–763,685)

75,000 (12,501–418,785)

0.289

0.45

0.0039

LIPS

 > 13

69,242 (3460–497,302)

27,764 (4566–654,324)

0.0419

  

RBA

0–13

136 (24–921)

69 (18–258)

0.0882

0.138

0.426

RBA

 > 13

70 (19–723)

46 (13–708)

0.12

  

Confirmatory study

LIPS

0–13

76,812 (25,069–3,390,545)

102,923 (27,941–1,594,069)

0.918

0.0202

0.0037

LIPS

 > 13

31,055 (5109–366,663)

31,473 (4528–233,670)

0.802

  

RBA

0–13

62 (21–1136)

76 (17–651)

0.605

0.761

0.835

RBA

 > 13

62 (8–1116)

64 (15–463)

0.736

  
  1. LIPS and RBA results are reported according to age groups: childhood patients (exploratory study, n = 11; confirmatory study, n = 11), childhood controls (exploratory study, n = 21; confirmatory study, n = 10), adult patients (exploratory study n = 32; confirmatory study, n = 20), adult controls (exploratory study, n = 43; confirmatory study, n = 44). AU and U/ml are referred to LIPS and RBA results, respectively. Indicated p-values refer to Mann–Whitney U tests comparing A/H1N1 HA antibodies levels between: patients and age-matched controls (p1), narcolepsy childhood and adolescent/adult patients (p2), healthy childhood and adolescent/adult controls (p3).
Back to article page